Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis-Reference-Cited by-同舟云学术

Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis

Published:2023-03 Issue: Volume:160 Page:105382
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Ordaya Eloy E.^ORCID,Vergidis Paschalis,Razonable Raymund R.,Yao Joseph D.,Beam Elena

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference13 articles.

1. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization;Planas;Nature,2022

2. Resistance mutations in SARS-CoV-2 Omicron variant in patients treated with sotrovimab;Vellas;Clin. Microbiol. Infect.,2022

3. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis;Lee;BMJ,2022

4. U.S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab). https://www.fda.gov/media/154701/download. Accessed 23 Aug 2022.

5. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19;Levin;N. Engl. J. Med.,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients;Biomolecules;2023-10-18

2. Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions;Expert Opinion on Biological Therapy;2023-06-18

3. SARS‐CoV‐2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients;Journal of Medical Virology;2023-06